Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas

Leukemia

Volumn 25, Issue 12, 2011, Pages 1882-1890

  Dejean, E ^a   Renalier, M H ^b   Foisseau, M ^a   Agirre, X ^c   Joseph, N ^b   De Paiva, G R ^d   Al Saati, T ^e   Soulier, J ^f,g   Desjobert, C ^a   Lamant, L ^a,h   Prosper F ^c   Felsher, D W ⁱ   Cavaille J ^b   Prats, H ^a   Delsol, G ^a,h   Giuriato, S ^a,h   Meggetto, F ^a,h  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b Université Paul Sabatier   (France)

^c UNIVERSITY OF NAVARRA   (Spain)

^d CHU RANGUEIL   (France)

^e CHU PURPAN   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g UNIVERSITÉ PARIS DIDEROT   (France)

^h European Research Initiative on ALCL (ERIA)   (Austria)

ⁱ STANFORD UNIVERSITY   (United States)

Author keywords

lymphomas; microRNA; onco ALK; VEGF

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; MICRORNA; MICRORNA 16; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HYPOXIA; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RNA TRANSLATION; TUMOR GROWTH;

ANIMALS; ANOXIA; BLOTTING, NORTHERN; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; DNA METHYLATION; DOWN-REGULATION; EMBRYO, MAMMALIAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 83555174323     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.168     Document Type: Article

References (49)

1. Moehler TM, Neben K, Ho AD, Goldschmidt H. Angiogenesis in hematologic malignancies. Ann Hematol 2001; 80: 695-705. (Pubitemid 34041426)
2. Salven P. Angiogenesis in lymphoproliferative disorders. Acta Haematol 2001; 106: 184-189. (Pubitemid 34124158)
3. Ruan J, Hajjar K, Rafii S, Leonard JP. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol 2009; 20: 413-424.
4. Roskoski Jr R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007; 62: 179-213. (Pubitemid 46679285)
5. Bastide A, Karaa Z, Bornes S, Hieblot C, Lacazette E, Prats H et al. An upstream open reading frame within an IRES controls expression of a specific VEGF-A isoform. Nucleic Acids Res 2008; 36: 2434-2445. (Pubitemid 351567014)
6. Touriol C, Bornes S, Bonnal S, Audigier S, Prats H, Prats AC et al. Generation of protein isoform diversity by alternative initiation of translation at non-AUG codons. Biol Cell 2003; 95: 169-178. (Pubitemid 36889219)
7. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597-610.
8. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005; 122: 6-7. (Pubitemid 40977933)
9. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 2009; 60: 167-179.
10. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009; 4: 199-227.
11. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006; 5: 2220-2222. (Pubitemid 44546557)
12. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008; 15: 261-271.
13. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009; 113: 6669-6680.
14. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006; 1: e116.
15. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284. (Pubitemid 24107549)
16. Arber DA, Sun LH, Weiss LM. Detection of the t(2;5)(p23;q35) chromosomal translocation in large B-cell lymphomas other than anaplastic large cell lymphoma. Hum Pathol 1996; 27: 590-594. (Pubitemid 26187284)
17. Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 1997; 89: 1483-1490. (Pubitemid 27097438)
18. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999; 59: 2776-2780. (Pubitemid 29283106)
19. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-1203. (Pubitemid 350235027)
20. Marzec M, Liu X, Wong W, Yang Y, Pasha T, Kantekure K et al. Oncogenic kinase NPM/ALK induces expression of HIF1alpha mRNA. Oncogene 2010; 30: 1372-1378.
21. Brugieres L, Quartier P, Le Deley MC, Pacquement H, Perel Y, Bergeron C et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children-a report from the French Society of Pediatric Oncology. Ann Oncol 2000; 11: 53-58. (Pubitemid 30084579)
22. Williams DM, Hobson R, Imeson J, Gerrard M, McCarthy K, Pinkerton CR. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol 2002; 117: 812-820. (Pubitemid 34639241)
23. Armstrong F, Lamant L, Hieblot C, Delsol G, Touriol C. TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins. Eur J Cancer 2007; 43: 640-646. (Pubitemid 46509444)
24. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009; 420: 345-361.
25. Giuriato S, Faumont N, Bousquet E, Foisseau M, Bibonne A, Moreau M et al. Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. Cancer Biol Ther 2007; 6: 1318-1323. (Pubitemid 351590389)
26. Giuriato S, Foisseau M, Dejean E, Felsher DW, Al Saati T, Demur C et al. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. Blood 2010; 115: 4061-4070.
27. Delsol GFB, Mûller-hermelink HK, Campo E, Jaffe ES, Gascoyne RD, Stein H et al. Anaplastic Large Cell Lymphoma, ALK-Positive. IARC Press: Lyon, 2008, pp 312-316.
28. Mason DYHN, Delsol G, Stein H, Campo E, Kinney MC, Jaffe ES et al. Anaplastic Large Cell Lymphoma, ALK-Negative. IARC Press: Lyon, 2008, pp 317-319.
29. Karaa ZS, Iacovoni JS, Bastide A, Lacazette E, Touriol C, Prats H. The VEGF IRESes are differentially susceptible to translation inhibition by miR-16. Rna 2009; 15: 249-254.
30. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6 (12 Pt 1): 3314-3322.
31. Perez-Pinera P, Chang Y, Astudillo A, Mortimer J, Deuel TF. Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. Biochem Biophys Res Commun 2007; 358: 399-403. (Pubitemid 46755722)
32. Piccaluga PP, Gazzola A, Mannu C, Agostinelli C, Bacci F, Sabattini E et al. Pathobiology of anaplastic large cell lymphoma. Adv Hematol 2010; 2010: 345053.
33. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11-23.
34. Turner SD, Alexander DR. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? Leukemia 2005; 19: 1128-1134. (Pubitemid 40945993)
35. Salaverria I, Bea S, Lopez-Guillermo A, Lespinet V, Pinyol M, Burkhardt B et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 2008; 140: 516-526. (Pubitemid 351230071)
36. Youssif C, Goldenbogen J, Hamoudi R, Carreras J, Viskaduraki M, Cui YX et al. Genomic profiling of pediatric ALK-positive anaplastic large cell lymphoma: a Children's Cancer and Leukaemia Group Study. Genes Chromosomes Cancer 2009; 48: 1018-1026.
37. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
38. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2010; 364: 775-776.
39. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-1739.
40. Wodarz D, Komarova NL. Emergence and prevention of resistance against small molecule inhibitors. Semin Cancer Biol 2005; 15: 506-514. (Pubitemid 41318049)
41. Chabot S, Jabrane-Ferra N, Bigot K, Provost A, Golzio M, Tabiasco J et al. A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. J Exp Med 2011; 208: 973-986.
42. Fons P, Chabot S, Cartwright JE, Lenfant F, L'Faqihi F, Giustiniani J et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood 2006; 108: 2608-2615.
43. Palazzo A, Iacovelli R, Cortesi E. Past, present and future of targeted therapy in solid tumors. Curr Cancer Drug Targets 2010; 10: 433-461.
44. Medinger M, Mross K. Clinical trials with anti-angiogenic agents in hematological malignancies. J Angiogenes Res 2010; 2: 10.
45. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 2010; 39: 761-772.
46. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007; 6: 5.
47. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, Martin-Subero JI, Cordeu L, Garate L et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 2009; 69: 4443-4453.
48. Henke JI, Goergen D, Zheng J, Song Y, Schuttler CG, Fehr C et al. microRNA-122 stimulates translation of hepatitis C virus RNA. Embo J 2008; 27: 3300-3310.
49. Jopling CL. Regulation of hepatitis C virus by microRNA-122. Biochem Soc Trans 2008; 36 (Pt 6): 1220-1223.